Inhibition of matrix metalloproteinases increases PPAR-α and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model

被引:29
作者
Alwayn, Ian P. J.
Andersson, Charlotte
Lee, Sang
Arsenault, Danielle A.
Bistrian, Bruce R.
Gura, Kathleen M.
Nose, Vania
Zauscher, Blanca
Moses, Marsha
Puder, Mark
机构
[1] Childrens Hosp, Dept Surg, Boston, MA 02115 USA
[2] Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA
[3] Childrens Hosp, Dept Pharm, Boston, MA 02115 USA
[4] Childrens Hosp, Dept Radiol, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[6] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA
[7] Erasmus MC, Dept Surg, Rotterdam, Netherlands
来源
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY | 2006年 / 291卷 / 06期
关键词
matrix metalloproteinase; nonalcoholic fatty liver disease; TNF-alpha; PPAR-alpha;
D O I
10.1152/ajpgi.00047.2006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Steatosis is a prominent feature of nonalcoholic fatty liver disease and a potential promoter of inflammation. Injury leading to cirrhosis is partly mediated by dysregulation of matrix protein turnover. Matrix metalloproteinase (MMP) inhibitors protect mice from lethal TNF-alpha induced liver injury. We hypothesized that Marimastat, a broad-spectrum MMP and TNF-alpha converting enzyme (TACE) inhibitor, might modulate this injury through interruption of inflammatory pathways. Triglyceride and phospholipid levels (liver, serum) and fatty acid profiles were used to assess essential fatty acid status and de novo lipogenesis as mechanisms for hepatic steatosis. Mice receiving a fat-free, high-carbohydrate diet (HCD) for 19 days developed severe fatty liver infiltration, demonstrated by histology, magnetic resonance spectroscopy, and elevated liver function tests. Animals receiving HCD plus Marimastat (HCD+MAR) were comparable to control animals. Increased tissue levels of peroxisome proliferator activated receptor-alpha (PPAR-alpha), higher levels of serum IL-6, and decreased levels of serum TNF-alpha receptor II were also seen in the HCD+MAR group compared with HCD-only. In addition, there was increased phosphorylation, and likely activation, of PPAR-alpha in the HCD+MAR group. PPAR-alpha is a transcription factor involved in beta-oxidation of fatty acids, and IL-6 is a hepatoprotective cytokine. Liver triglyceride levels were higher and serum triglyceride and phospholipid levels lower with HCD-only but improved with Marimastat treatment. HCD-only and HCD+MAR groups were essential fatty acid deficient and had elevated rates of de novo lipogenesis. We therefore conclude that Marimastat reduces liver triglyceride accumulation by increasing fat oxidation and/or liver clearance of triglycerides. This may be related to increased expression and activation of PPAR-alpha or IL-6, respectively.
引用
收藏
页码:G1011 / G1019
页数:9
相关论文
共 67 条
  • [1] SEPARATION OF ACIDIC AND NEUTRAL LIPIDS BY AMINOPROPYL-BONDED SILICA-GEL COLUMN CHROMATOGRAPHY
    ALVAREZ, JG
    TOUCHSTONE, JC
    [J]. JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 577 (01): : 142 - 145
  • [2] Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease
    Alwayn, IPJ
    Gura, K
    Nosé, V
    Zausche, B
    Javid, P
    Garza, J
    Verbesey, J
    Voss, S
    Ollero, M
    Andersson, C
    Bistrian, B
    Folkman, J
    Puder, M
    [J]. PEDIATRIC RESEARCH, 2005, 57 (03) : 445 - 452
  • [3] Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency
    Alwayn, IPJ
    Javid, PJ
    Gura, KM
    Nosé, V
    Ollero, M
    Puder, M
    [J]. HEPATOLOGY, 2004, 39 (04) : 1176 - 1177
  • [4] Nonalcoholic fatty liver disease
    Brunt, Elizabeth M.
    Wong, Vincent W. -S.
    Nobili, Valerio
    Day, Christopher P.
    Sookoian, Silvia
    Maher, Jacquelyn J.
    Bugianesi, Elisabetta
    Sirlin, Claude B.
    Neuschwander-Tetri, BrentA.
    Rinella, Mary E.
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2015, 1
  • [5] Contribution of TNF-α converting enzyme and proteinase-3 to TNF-α processing in human alveolar macrophages
    Armstrong, L
    Godinho, SIH
    Uppington, KM
    Whittington, HA
    Millar, AB
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2006, 34 (02) : 219 - 225
  • [6] Prevalence of and risk factors for hepatic steatosis in northern Italy
    Bellentani, S
    Saccoccio, G
    Masutti, F
    Crocè, LS
    Brandi, G
    Sasso, F
    Cristanini, G
    Tiribelli, C
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 132 (02) : 112 - 117
  • [7] BENJAMIN DR, 1981, AM J CLIN PATHOL, V76, P276
  • [8] The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
    Brown, MS
    Goldstein, JL
    [J]. CELL, 1997, 89 (03) : 331 - 340
  • [9] Effect of PPAR-α and -γ agonist on the expression of visfatin, adiponectin, and TNF-α in visceral fat of OLETF rats
    Choi, KC
    Ryu, OH
    Lee, KW
    Kim, HY
    Seo, JA
    Kim, SG
    Kim, NH
    Choi, DS
    Baik, SH
    Choi, KM
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 336 (03) : 747 - 753
  • [10] Hepatic steatosis and type 2 diabetes mellitus.
    Clark J.M.
    Diehl A.M.
    [J]. Current Diabetes Reports, 2002, 2 (3) : 210 - 215